Literature DB >> 23813142

Pulmonary complications of treatment with pegylated interferon for hepatitis C infection-two case reports.

Vinod S Hegade1, Ruchit Sood, Dinesh Saralaya, Sulleman Moreea.   

Abstract

Pegylated interferon (Peg-IFN) in combination with ribavirin is the standard of care in the treatment of chronic hepatitis C (HCV). Peg-IFN is known to have a number of side effects but severe respiratory complications are uncommon. We report two cases, one of Peg-IFN induced interstitial pneumonitis (IP) and the other of bronchiolitis obliterans organising pneumonia (BOOP) in patients with chronic hepatitis C infection. In general, respiratory complications of Peg-IFN are mild and resolve with withdrawal of Peg-IFN. However, as illustrated in our first case fatal interstitial pneumonitis can occur. We present a review of the available literature on Peg-IFN induced lung toxicity. In conclusion, pulmonary toxicity with Peg-IFN is rare but fatality can occur. We highlight the importance of maintaining a high index of suspicion for early diagnosis and prompt treatment, which includes withdrawal of Peg-IFN and consideration of corticosteroid treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23813142

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  2 in total

Review 1.  Daclatasvir: potential role in hepatitis C.

Authors:  Choongho Lee
Journal:  Drug Des Devel Ther       Date:  2013-10-16       Impact factor: 4.162

2.  Interstitial pneumonia associated to peginterferon alpha-2a: A focus on lung function.

Authors:  Arturo Cortés-Telles
Journal:  Lung India       Date:  2016 Mar-Apr
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.